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Abstract
Introduction No published clinical trial data are available to
inform the use of enzyme replacement therapy (ERT) in
patients with the severe (neuropathic) phenotype of
mucopolysaccharidosis II (MPS II). Current guidelines rec-
ommend ERT administered intravenously be used on a trial
basis in this population.
Aims/methods A retrospective chart review was conducted at
five international centers for this case series of 22 patients with
neuropathic MPS II who received intravenous idursulfase
0.5 mg/kg weekly for at least 2 consecutive years. We collected
data about urinary glycosaminoglycan levels, adverse events,
and the following somatic signs/symptoms: skeletal disease,
joint range of motion, liver/spleen size, respiratory infections,
cardiac disease, diarrhea, skin/hair texture, and hospitalizations.
Results The age at diagnosis was 2 months to 5 years, and the
age at idursulfase initiation was between 18 months and
21 years. One of 22 patients experienced improvements in seven
somatic signs/symptoms; 17/22 experienced improvements in
five to six somatic signs/symptoms; and 4/22 experienced im-
provements in four somatic signs/symptoms. None experienced
fewer than four improvements. No new safety concerns arose.
Infusion-related reactions were experienced by 4/22 patients but
were successfully managed using accepted strategies.
Conclusions Long-term treatment with idursulfase was asso-
ciated with improvements in somatic manifestations in this
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case series of patients with neuropathic MPS II. The family
and medical team should maintain open lines of communica-
tion to make treatment decisions that take into consideration
the benefits and limitations of ERT in this population.
Abbreviations
%FVC Percent predicted forced vital capacity
6MWT 6 minute walk test
ADA Anti-drug antibodies
ERT Enzyme replacement therapy







ULN Upper limit of normal
Introduction
Mucopolysaccharidosis II (MPS II, Hunter syndrome, OMIM
309900) is an X-linked lysosomal storage disorder with an
incidence of 0.3–0.71 per 100,000 live births (Bach et al 1973;
Burton and Giugliani 2012). MPS II is caused by a deficiency
in the enzyme iduronate-2 sulfatase (I2S, EC 3.1.6.13), lead-
ing to the accumulation of the glycosaminoglycans (GAGs)
dermatan sulfate and heparan sulfate in lysosomes. Excessive
storage of these GAGs causes a variety of clinical manifesta-
tions, including coarse facies, hearing loss, cardiac valve
disease, restrictive and obstructive airway disease, recurrent
upper respiratory infections, hepatosplenomegaly, skeletal ab-
normalities, joint contractures, short stature, and a character-
istic skin rash (Martin et al 2008; Neufeld andMuenzer 2001).
MPS II is a progressive disease that presents a high burden
of morbidity and a reduced life expectancy (Martin et al 2008;
Neufeld and Muenzer 2001). The disorder manifests on a
spectrum of severity from attenuated to severe. Approximately
one-third of patients have attenuated disease, with a gradual
onset, lack of cognitive involvement, and life expectancy into
the fourth through sixth decade of life (Young andHarper 1982;
Young et al 1982a). The remaining two-thirds have severe
disease characterized by the onset of signs and symptoms
before the age of 3 years, progressive cognitive impairment,
and behavioral disturbances. Natural history data from untreat-
ed severe patients indicate a life expectancy only into the
second or third decade (Young and Harper 1983; Young et al
1982a, b). Of note, disease severity does not refer to the extent
or seriousness of somatic signs and symptoms but only to the
rate of disease progression and the presence or lack of cognitive
involvement. All patients, regardless of disease severity,
experience similar somatic manifestations that reduce the qual-
ity of life of both patients and caregivers (Martin et al 2008).
Idursulfase (Elaprase®, Shire Human Genetic Therapies,
Inc., Lexington, MA, USA), a recombinant human I2S en-
zyme replacement therapy (ERT), was approved in the United
States in 2006 and in Europe in 2007 for the treatment ofMPS
II. It is currently available in over 50 countries. The approval
of idursulfase was based on a pivotal phase II/III study which
enrolled 96 patients between the ages of 5 and 31 years
(Muenzer et al 2006). Patients were randomized to receive
weekly or every-other-week infusions of idursulfase 0.5mg/kg
or placebo infusions for 53 weeks. The primary efficacy
endpoint was a composite of distance walked in 6 min
(6MWT) and improvements in percent predicted forced vital
capacity (%FVC). The study found that patients in both ERT
groups exhibited significant improvements in the primary
composite endpoint compared with those in the placebo
group, with the greatest gains seen in the weekly treatment
group (Muenzer et al 2006). All 94 patients who completed
the placebo-controlled study were enrolled into an open-label
extension trial in which they received weekly infusions of
0.5 mg/kg idursulfase for an additional 2 years. Patients
experienced improvements in absolute FVC, 6MWT distance,
liver and spleen volumes, shoulder range of motion, and
parent- and child-assessed Child Health Assessment Ques-
tionnaire Disability Index Scores (Muenzer et al 2011).
Because of the difficulties involved in collecting FVC and
6MWT data from cognitively impaired patients, the pivotal
trial and its extension enrolled only individuals with attenuated
phenotypes. While there are no clinical trial data available for
severe patients, clinical experience suggests that severe pa-
tients can experience certain somatic improvements and
caregiver-reported improvements in quality of life. In a recent
consensus report, a panel of experts described their experience
with idursulfase in 66 patients with the severe phenotype
(Muenzer et al 2012). After at least 1 year of ERT, 50 of these
patients experienced at least one type of somatic improvement.
These improvements included reductions in the frequency of
respiratory infections, reductions in liver volume and sleep
apnea, and improvements in joint range of motion. In 61 out
of 66 cases, physicians and families found sufficient benefit to
continue ERT. Current U.S. and European guidelines suggest
initiating a 6- to 18-month trial of ERT in severe MPS II
patients to assess the response before stopping or continuing
therapy (Muenzer et al 2012; Scarpa et al 2011). Here we
describe our experiences with long-term (≥ 2 years) ERT in a
series of severe MPS II patients from five international centers.
Methods
A retrospective chart review was conducted at the authors’
institutions to identify all MPS II patients who were treated
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with intravenous (IV) idursulfase according to the prescribing
information (0.5 mg/kg once weekly) continuously for at least
24 consecutive months. All patients had neuropathic MPS II
as confirmed by formal developmental testing or by investi-
gator report.
The following data were collected from the patients’
records:
& Liver and/or spleen size as measured via palpation and/or
imaging studies.
& Frequency of respiratory infections as reported by
caregivers.
& Texture of hair/skin as observed during physical
examination.
& Frequency of diarrhea as reported by caregivers.
& Joint range of motion as observed during physical
examination.
& Skeletal disease as measured via imaging studies.
& Cardiac disease as measured via echocardiogram and/or
electrocardiogram.
& Urinary glycosaminoglycan (uGAG) levels as assessed by
chart review.
& Disease-related hospitalizations as assessed by chart review.
& Cognitive function as assessed by formal developmental
evaluation and/or by investigator impression if formal
assessments were not performed.
Testing for IgG and IgE antibodies to idursulfase, when
reported, was conducted by the Bioanalytical and Biomarker




Patients received ERT at five international centers. In Brazil,
three patients received ERT at one center. In Germany, 12
patients received ERTat two centers, and in the United States,
seven patients received ERT in two centers. The mean age at
diagnosis was 2.8 years (range: 0.2–5.0 years). The mean age
at the start of ERT was 6.8 years (range: 1.5–21.0 years), and
the mean duration of therapy was 4.7 years (range: 2.0–
6.0 years). Individual patient demographics are presented in
Supplementary Table 1.
Safety
Four out of 22 (18 %) patients experienced at least one
infusion-related reaction (IRR) at any time during the course
of ERT (Supplementary Table 1). No other adverse events
were observed.
Prophylactic medications to prevent IRRs were adminis-
tered to 10/22 (45 %) patients. Of these, four patients had
experienced previous IRRs. The remaining six patients were
administered prophylactic medications without a history of
IRRs, and none of them developed reactions. Of the ten
patients who received prophylactic medications, seven pa-
tients received antihistamines alone, one of whom had expe-
rienced a previous IRR. The remaining three patients received
antihistamines plus steroids; all of these patients had experi-
enced prior IRRs.
Of the seven patients who were treated with antihistamines,
two were weaned off all prophylactic medication after approx-
imately 1 year. Neither of these patients had experienced an
IRR. Of the three patients who were treated with antihista-
mines plus steroids, two were weaned to antihistamines alone
after approximately 1 year but continued to remain free of
subsequent IRRs.
Seventeen patients were tested for IgG and IgE anti-drug
antibodies (ADA). Of these patients, six (35 %) developed
IgG ADAs, and none developed IgE ADAs. No clear corre-
lation between ADA positivity and IRRs was observed. Only
two of the six ADA-positive patients experienced IRRs
(Table 1).
Response to treatment
According to our observations, all of the patients experienced
somatic improvements on ERT (Table 2). The majority of the
patients (18 patients, 82%) had improvements in five to seven
signs and symptoms, and all of the patients experienced
improvements in at least four of the somatic signs and symp-
toms evaluated. Of the signs and symptoms evaluated
(Table 3), all patients experienced reductions in liver and/or
spleen size (as seen on imaging studies or physical examina-
tion), reduced frequency of respiratory infections (as recorded
in patient charts), and improvements in hair and/or skin tex-
ture (as judged by the investigator). Eleven out of 14 (79 %)
patients who had been hospitalized for a MPS II-related
reason prior to starting ERTshowed a reduction in the number
of disease-related hospitalizations on ERT as recorded in the
patients’ charts. Improvement in joint range of motion was
reported for 7/21 patients (33 %), and another 13/21 patients
(62 %) showed stabilization of joint disease. Note that mea-
surement techniques were not standardized among centers;
Table 1 Anti-drug antibody and infusion-related reaction status among
cases tested (n=17)
IRR positive IRR negative
ADA positive 2 4
ADA negative 3 8
ADA anti-drug antibodies, IRR infusion-related reaction
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however, an increase in joint range of motion of at least 10° was
considered an improvement. Skeletal disease, as assessed by
imaging studies, was stabilized in 19/22 (86 %) patients. Cardiac
disease, as assessed by electrocardiogram and/or echocardio-
gram, was also stabilized in 19/22 (86 %) patients. Stabilization
can be considered a positive response to treatment in a progres-
sive disease like MPS II. Interestingly, one patient (patient 4)
experienced partially improved cardiac disease on treatment with
idursulfase. His echocardiograms prior to treatment revealed
mild left ventricular dysfunction and abnormal septal motion.
On treatment, he consistently had normal left ventricular systolic
function. He also had evidence of mild thickening of the mitral
valve, which has been stable on 6 years of treatment.
Urinary GAG levels were tested, and individual changes in
uGAG levels are detailed in Fig. 1. A decrease in uGAG levels
compared with baseline was observed in 20/22 (91 %) pa-
tients, with decreases ranging from 22 to 97 %. Of note, two
patients (patients 6 and 14) did not have baseline test results
available; we therefore calculated the percent change in
uGAG level between the first available test result and the last
available test result. Of the 22 patients, two demonstrated an
increase in uGAG levels. Patient 16 was ADA-negative but
did experience IRRs. His baseline uGAGvalue was 10.14mg/
mmol creatinine (upper limit of normal (ULN): 8.30mg/mmol
creatinine). This level rose to a high of 23.52 mg/mmol
creatinine at approximately 6 months after the start of ERT.
At the last available measurement 3 years after the start of
ERT, the level had fallen to 13.58 mg/mmol creatinine.
Despite the fluctuations in uGAG level, he experienced im-
provements in liver and spleen size, frequency of respiratory
infections, hair and skin texture, and the number of disease-
related hospitalizations on ERT. His joint range of motion,
skeletal disease, and cardiac disease stabilized on ERT. The
second patient, patient 14, was ADA-positive and had no
IRRs. His case is complicated by a lack of a true baseline
measurement. His uGAG levels were nearly normal at
7.86 mg/mmol creatinine at 6 months on ERT (ULN:
7.70 mg/mmol creatinine), then rose to a high of 25.09 mg/
mmol creatinine 2 years after the start of ERT. At the last
available measurement, 4 years after the start of ERT, his
uGAG levels were 15.93 mg/mmol creatinine. Despite elevat-
ed uGAG levels, this patient experienced improvements in
liver and spleen size, frequency of respiratory infections, hair
and skin texture, and the number of disease-related hospital-
izations. His skeletal and cardiac disease parameters remained
stable on ERT, although his joint range of motion limitations
progressed.
Cognitive disease was assessed by formal developmen-
tal evaluation or by investigator impression when formal
testing was not performed. In this case series, cognitive
disease progressed in 17/22 (77 %) patients and stabilized
in 3/22 (14 %). Slight improvements were reported for
2/22 (9 %) patients, both of whom were evaluated by
investigator impression and not by formal developmental
testing. Because idursulfase does not cross the blood–brain
barrier (Boado et al 2013), these improvements are likely
due to improved sleep or respiration leading to the chil-
dren having greater interactions with their environments
and are not due to any direct action of the drug upon the
brain.
Discussion
Because clinical trial data for the use of idursulfase to treat
severe (neuropathic) MPS II are lacking, there has been much
interest in the long-term clinical course of such patients. In a
recent consensus report, a panel of experts pooled their expe-
riences with treating 66 severe patients with ERT and
Table 2 Number of patients with somatic signs or symptoms assessed as









Fewer than 4 0
ERT enzyme replacement therapy
Table 3 Somatic response on
enzyme replacement therapy
aAssessed by physical exam
bAssessed by imaging studies
c Assessed by caregiver report
d Assessed by electrocardiogram
and/or echocardiogram
Sign/symptom Improvement Stabilization Disease progression
Liver and/or spleen sizea,b 22/22 (100 %) 0 0
Frequency of respiratory infectionsc 22/22 (100 %) 0 0
Texture of hair and/or skina 21/21 (100 %) 0 0
Disease-related hospitalizations 11/14 (79 %) 3/14 (21 %) 0
Diarrheac 4/9 (44 %) 5/9 (56 %) 0
Joint range of motion (1 or more joints)a 7/21 (33 %) 13/21 (62 %) 1/21 (5 %)
Skeletal diseaseb 2/22 (9 %) 19/22 (86 %) 1/22 (5 %)
Cardiac diseased 1/22 (5 %) 19/22 (86 %) 2/22 (9 %)
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concluded that somatic signs and symptoms were improved in
the majority. The panel recommended that a trial of 6 to
12 months’ treatment be offered to severe patients (Muenzer
et al 2012). Follow-up examinations are recommended at 6- to
12-month intervals during the trial of treatment (Scarpa et al
2011). In the present case series, the long-term effects of ERT
with idursulfase were analyzed in 22 patients with severeMPS
II who received ERT for at least 2 consecutive years at five
international centers. In agreement with the expert consensus
panel, we found that all of our patients experienced improve-
ments in at least four of the somatic signs and symptoms
evaluated, and 82 % experienced improvements in five to
seven somatic signs and symptoms (Table 2).
Long-term treatment with idursulfase was generally well-
tolerated in this case series. The only reported adverse events
were IRRs, with 4/22 (18 %) patients experiencing manage-
able reactions. These included extreme irritability, hyperten-
sion, allergic conjunctivitis, urticaria factita, cough,
tachypnea, shivering, and vomiting. All resolved with stan-
dard care. We did not find a clear connection between IRRs
and ADA positivity (Table 1). All four patients who experi-
enced IRRs were successfully premedicated before subse-
quent infusion visits with prophylactic antihistamines (n=1)
or antihistamines plus steroids (n=3). Two patients in the
latter group were later weaned to antihistamines alone with
no further IRRs.
As an MPS II expert consensus panel has previously point-
ed out, a major challenge in evaluating the response to ERT in
severe MPS II patients is the lack of assessment tools that are
validated in this population (Muenzer et al 2012). Cognitive
decline and behavioral difficulties decrease quality of life for
patients with MPS II and their caregivers (Bax and Colville
1995), but it is clear that IV idursulfase treatment does not
address these disease features (Muenzer et al 2012; Wraith
et al 2008) because the large protein does not appear to cross
the blood–brain barrier (Boado et al 2013). Like Muenzer and
colleagues (Muenzer et al 2012), we do consider, however,
that improvements in somatic signs and symptoms may be
experienced by severe patients and can help improve the
quality of patients’ and caregivers’ lives. For example, fre-
quent respiratory infections leading to hospitalization are a
common finding in MPS II, causing distress for patients and
caregivers as well as lost time at work for caregivers
(Muhlebach et al 2011; Young et al 1982a). In the current
case series, 100 % of patients experienced a reduction in the
frequency of respiratory infections with ERT, and 79 % had
reductions in the number of disease-related hospitalizations as
judged by the managing physician who reviewed patient
records (Table 3). In our experience, reductions in
organomegaly can improve breathing and reduce abdominal
pain, nausea, and early satiety among MPS II patients. All of
our patients in this case series experienced reductions in liver
and/or spleen size on ERT. Joint contractures and skeletal
deformities associated with dysostosis multiplex result in
significant restrictions in mobility and progressive disability
in MPS II (Link et al 2010; Wraith et al 2008). In the current
study, joint range of motion improved in 33 % of patients, and
stabilized in 62 % of patients. In addition, 86 % of patients
showed stabilization of skeletal disease, which may be con-
sidered a benefit of treatment for a progressive disease such as
MPS II. It has been previously stated that an important goal of
therapy is the improvement in quality of life for the patient and
family, so a perception by the family of improved quality of
life should be taken into strong consideration when deciding
Fig. 1 Percent change in urinary
glycosaminoglycan (uGAG)
levels from baseline at last
available test result for severe
MPS II patients on long-term
enzyme replacement therapy
(ERT). *First available uGAG test
result for patient 6 was after
7 months of ERT and for patient
14 was after 6 months of ERT. No
baseline data are available. Here
we report percent change between
first available and last available
uGAG test results
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whether or not to continue therapy (Muenzer et al 2012). We
agree with this approach and suggest not prohibiting cogni-
tively disabled patients from trying a treatment that may
produce clinically relevant improvements in multiple somatic
features, thereby lessening the burden of illness for the patient
and family.
Urinary GAGs are a useful endpoint in order to observe the
biochemical effects of idursulfase treatment. Urinary GAG
levels were generally reduced on ERT, with 91 % of patients
experiencing a decrease in uGAG levels as compared with
baseline (Fig. 1). Two patients experienced an increase in
uGAG levels while receiving idursulfase, but this increase
did not clearly correspond with ADA, as patient 14 was
ADA positive and patient 16 was ADA negative. Both pa-
tients experienced four or more somatic improvements on
ERT despite increased uGAG levels. It is possible that these
patients’ measurements may have been misleading, as indi-
vidual uGAGmeasurements vary from day to day and even at
different times during the day. The picture is somewhat more
complicated for patient 14, who lacks baseline data and whose
earliest uGAG test was performed after 6 months of ERT. The
result at that point was nearly normal (7.86 mg/mmol creati-
nine; ULN: 7.70mg/mmol creatinine). Thus, data from patient
14 should be considered with caution.
As expected for severe patients, cognitive disease
progressed in 17/22 (77 %) patients and stabilized in 3/22
(14 %), as assessed by formal developmental evaluation or by
investigator impression when formal evaluations were not
performed. Slight improvements were reported for two pa-
tients. This likely reflects an increased ability of these patients
to interact with others and with their environment due to
improved mobility, improved sleep, and/or reductions in re-
spiratory disease burden, since idursulfase does not cross the
blood–brain barrier (Boado et al 2013). In our experience,
families of severeMPS II patients often choose to initiate ERT
despite the presence of cognitive impairment because they
believe that somatic improvements will improve the quality
of the patient’s life. This finding is in keeping with a published
survey of MPS families, which found that 77 % of respon-
dents were in favor of starting ERT in a patient with a severe
phenotype, even knowing that treatment cannot alter the in-
tellectual deterioration associated with the disease (Coman
et al 2008).
In summary, this retrospective case series provides details
on our experiences with treating severe MPS II patients with
ERT for more than 2 years continuously. Treatment was
associated with improvements in somatic signs and symptoms
of the disease for all patients, and it was generally well
tolerated. While ERT may provide benefits for severe MPS
II patients, families should make any treatment decisions in
concert with their child’s physician, with open lines of com-
munication regarding the possible benefits and limitations of
this treatment (Muenzer et al 2012; Scarpa et al 2011; Wraith
et al 2008). Criteria for discontinuation of ERT should be
thoroughly outlined before the start of therapy and evaluated
again after 6 to 12 months on treatment and every 18 to
24 months thereafter.
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